{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:00:57Z","timestamp":1794740457766,"version":"4.9.1"},"reference-count":44,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anaesthesiol Intensive Ther"],"abstract":"<jats:p>An increasing number of patients treated with novel antidiabetic drugs, including glucagon-like-peptide-1 receptor agonists (GLP-1RA), dual glucose-dependent insulinotropic polypeptide receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, are presenting in the perioperative period. GLP-1RAs are known to delay gastric emptying, although current data remain preliminary and somewhat conflicting. SGLT2 inhibitors may be associated with euglycemic ketoacidosis in the perioperative period. To assess residual gastric content, gastric ultrasound may serve as a valuable tool in stratifying aspiration risk. Various recommendations are available for the perioperative management of patients on GLP-1RAs or SGLT2 inhibitors. These are based largely on expert opinion and multi-society consensus.\nThis review aims to summarise the key perioperative considerations related to these drug classes and to familiarise practitioners with their pharmacological profiles. \nWe highlight their potential adverse effects and present current recommendations from professional organisations to support safe and effective perioperative management.<\/jats:p>","DOI":"10.5114\/ait\/208895","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:08:14Z","timestamp":1758524894000},"page":"231-238","source":"Crossref","is-referenced-by-count":5,"title":["New therapeutic agents for type 2 diabetes:  anaesthetic considerations. A narrative review"],"prefix":"10.5114","volume":"57","author":[{"given":"Oliwia","family":"Doroba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2396-8885","authenticated-orcid":false,"given":"Leszek","family":"Czupryniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5144-0776","authenticated-orcid":false,"given":"Filippo","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Andruszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3058-7984","authenticated-orcid":true,"given":"Mateusz","family":"Zawadka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref-1514045","doi-asserted-by":"publisher","DOI":"10.5837\/bjc.2024.023"},{"key":"ref-1514046","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196202"},{"key":"ref-1514047","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja"},{"key":"ref-1514048","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14212366"},{"key":"ref-1514049","doi-asserted-by":"crossref","unstructured":"Pinto EFA, Bastos MLS, Prates CG, Sander GB, Bumaguin DB, Bagatini A. Assessment of residual gastric volume by ultrasound prior to upper endoscopy: a prospective cohort study. Can J Anaesth 2025; 72: 233-241.","DOI":"10.1007\/s12630-024-02885-0"},{"key":"ref-1514050","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2024.12.019"},{"key":"ref-1514051","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-024-02719-z"},{"key":"ref-1514052","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2023.111091"},{"key":"ref-1514053","doi-asserted-by":"publisher","DOI":"10.1111\/anae.16454"},{"key":"ref-1514054","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-023-02549-5"},{"key":"ref-1514055","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2024.0111"},{"key":"ref-1514056","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-023-02521-3"},{"key":"ref-1514057","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-023-02440-3"},{"key":"ref-1514058","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2023.05.005"},{"key":"ref-1514059","doi-asserted-by":"publisher","DOI":"10.1002\/anr3.12278"},{"key":"ref-1514060","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.03.028"},{"key":"ref-1514061","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.003"},{"key":"ref-1514062","doi-asserted-by":"publisher","DOI":"10.1111\/anae.16541"},{"key":"ref-1514063","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S016"},{"key":"ref-1514064","unstructured":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2022. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463."},{"key":"ref-1514065","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0000000000002069"},{"key":"ref-1514066","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"ref-1514067","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101882"},{"key":"ref-1514068","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_496"},{"key":"ref-1514069","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"ref-1514070","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020199"},{"key":"ref-1514071","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"ref-1514072","doi-asserted-by":"publisher","DOI":"10.1111\/anae.16601"},{"key":"ref-1514073","unstructured":"Sanfilippo F, La Via L, Tigano S, Morgana A, La Rosa V, Astuto M. Trial sequential analysis. The evaluation of the robustness of metaanalyses findings and the need for further research. Euromediterranean Biomedical Journal 2021; 16: 104-107. DOI: https:\/\/doi.org\/10.3269\/ 1970-5492.2021.16.25."},{"key":"ref-1514074","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10424"},{"key":"ref-1514075","doi-asserted-by":"publisher","DOI":"10.1111\/anae.16504"},{"key":"ref-1514076","doi-asserted-by":"publisher","DOI":"10.1186\/s44158-022-00072-5"},{"key":"ref-1514077","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-031620-095920"},{"key":"ref-1514078","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01442-z"},{"key":"ref-1514079","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10065-7"},{"key":"ref-1514080","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14251"},{"key":"ref-1514081","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3342"},{"key":"ref-1514082","doi-asserted-by":"crossref","unstructured":"Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors \u2013 lessons from a case series and strategies to decrease incidence. Endocr Pract 2022; 28: 884-888. DOI: 10.1016\/ j.eprac.2022.06.006.","DOI":"10.1016\/j.eprac.2022.06.006"},{"key":"ref-1514083","unstructured":"National Institute for Health and Care Excellence. Type 2 Diabetes in Adults: Management NICE Guideline [NG28]. 2022. https:\/\/www.nice.org.uk\/guidance\/ng28 (Accessed: 13.11.2024)."},{"key":"ref-1514084","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-023-03174-8"},{"key":"ref-1514085","doi-asserted-by":"crossref","unstructured":"Standards of Care in Diabetes. The position of Diabetes Poland \u2013 2025. Current Topics in Diabetes 2025; 5: 1-158. DOI: https:\/\/doi.org\/ 10.5114\/ctd\/203685.","DOI":"10.5114\/ctd\/208094"},{"key":"ref-1514086","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002425"},{"key":"ref-1514087","unstructured":"Clinical Practice Recommendations regarding patients taking GLP-1 receptor agonists and dual GLP-1\/GIP receptor co-agonists prior to anaesthesia or sedation for surgical and endoscopic procedures. 2025. Available at: https:\/\/www.anzca.edu.au\/getContentAsset\/0f35028e-e371-4220-a49a-ddee877051c8\/80feb437-d24d-46b8-a858-4a\u00ad2a28b9b970\/Periprocedural-GLP-1-use-consensus-clinical-guide_P2.pdf?language=en (Accessed: 10.06.2025)."},{"key":"ref-1514088","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2025.2456441"}],"container-title":["Anaesthesiology Intensive Therapy"],"original-title":[],"link":[{"URL":"https:\/\/www.ait-journal.com\/pdf-208895-128621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ait-journal.com\/pdf-208895-128621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:08:16Z","timestamp":1758524896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ait-journal.com\/New-therapeutic-agents-for-type-2-diabetes-anaesthetic-considerations-A-narrative,208895,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"alternative-id":["208895"],"URL":"https:\/\/doi.org\/10.5114\/ait\/208895","relation":{},"ISSN":["1642-5758","1731-2531"],"issn-type":[{"value":"1642-5758","type":"print"},{"value":"1731-2531","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}